Veterans may be uniquely predisposed to developing CLL or MCL due to occupational exposures and clinicians in the VHA system must be prepared to treat these B-cell malignancies. BTKi agents oìer a potent therapeutic choice for veterans, who may be intolerant of traditional CIT-based regimens due to their age and comorbidities. To provide optimal care for veterans, VHA clinicians must be prepared with a comprehensive understanding of the current guidelines for using BTKi agents in frontline and R/R treatment settings for CLL and MCL, the role of drug resistance in covalent and noncovalent BTKi agents, considerations for selecting and sequencing BTKi agents, and the unique safety proíle of each agent. By gaining a deeper and more nuanced understanding of the role of BTKi agents in CLL and MCL, clinicians in the VHA system will be able to make more personalized therapy selections for veterans
- Provider:Medical Education Resources
- Activity Link: https://mycme.com
- Start Date: 2024-12-23 06:00:00
- End Date: 2024-12-23 06:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - Commercial Support: Source: AstraZeneca (Any division) - Amount: 50000.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence
- Provider Ship: Jointly Provided
- Registration: Open to all